Monthly Archives: July 2006

In Medicare Part D Failures, an Opportunity

As has been long awaited and discussed herein, many elderly are reaching the Medicare Part Donut-hole as evidenced by articles in both the Sunday New York Times and the Washington Post.  Both papers profile and document the surprise and fear … Continue reading

Posted in Pharma Industry Image, Pricing and Value | Comments Off on In Medicare Part D Failures, an Opportunity

Weekly Roundup – 7/28-06

Well, as the sun sets on our week, it is time for the Weekly Roundup.  So much has happened, my head is practically spinning.  I don’t know about the rest of you, but for me it has been a long … Continue reading

Posted in Weekly Roundup | Comments Off on Weekly Roundup – 7/28-06

Dr. Andrew C. von Eschenbach Confirmation Hearing

The Bush Administration has been in office five years.  There has been a confirmed commissioner in the office of the FDA for only 18 months out of that time.  The Senate Committee on Health, Education, Labor and Pensions has scheduled … Continue reading

Posted in FDA Image | Comments Off on Dr. Andrew C. von Eschenbach Confirmation Hearing

Kennedy Enzi and the Bucks for Enforcement

One of the touted aspects of the not-yet-introduced Kennedy Enzi bill aimed at FDA reform is the provision that would allow the FDA to monitor and fine drug companies for failure to meet up with post-marketing commitments.  QDIS reported on … Continue reading

Posted in Proposed Legislation | Comments Off on Kennedy Enzi and the Bucks for Enforcement

FDA Advisory Committees and Conflicts of Interest

Anyone who has been reading headlines has seen concerns raised by those on the Hill and among some consumer groups about the financial ties that exist between those who serve on Advisory Committees.  The issue was raised a few years … Continue reading

Posted in FDA Policy | Comments Off on FDA Advisory Committees and Conflicts of Interest